Brokerages Set Pfizer Inc. (NYSE:PFE) Target Price at $28.28

Pfizer Inc. (NYSE:PFE) has been given an average recommendation of “Hold” by the nineteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $28.3889.

A number of research analysts have recently issued reports on PFE shares. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Scotiabank assumed coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PFE. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Brookwood Investment Group LLC acquired a new position in shares of Pfizer in the first quarter worth $227,000. Avantax Advisory Services Inc. increased its position in shares of Pfizer by 5.9% during the first quarter. Avantax Advisory Services Inc. now owns 369,411 shares of the biopharmaceutical company’s stock worth $9,361,000 after acquiring an additional 20,421 shares during the period. Finally, HB Wealth Management LLC boosted its holdings in Pfizer by 25.7% in the first quarter. HB Wealth Management LLC now owns 249,328 shares of the biopharmaceutical company’s stock valued at $6,318,000 after purchasing an additional 50,968 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

Shares of NYSE PFE opened at $25.76 on Monday. The business’s 50 day moving average price is $25.01 and its 200-day moving average price is $24.60. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $146.46 billion, a price-to-earnings ratio of 13.70, a PEG ratio of 0.81 and a beta of 0.54. Pfizer has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts expect that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.